Egetis Therapeutics (EGTX) FDA Announcement summary

Introduction and purpose

• FDA granted a rolling NDA review for Emcitate (tiratricol) for MCT8 deficiency, following a successful pre-NDA meeting in October 2025 and Breakthrough Therapy Designation in July.

• The objective was to seek FDA advice and agreement on the NDA submission content, focusing on the clinical data package.

Details of approval or decision

• Rolling NDA submission for Emcitate will begin in December 2025, with a complete NDA targeted for early 2026 and FDA review completion expected in Q3 2026, aiming for Priority Review.

• NDA will be based on currently available clinical data from six sources, including Triac Trial I, Triac Trial II, ReTRIACt, EMC Cohort Study, EMC Survival Study, and the US Expanded Access Program.

• The ReTRIACt trial will be closed soon, with accrued data included in the NDA and its Statistical Analysis Plan revised to reflect its complementary role.

Impact on industry and stakeholders

• Emcitate is the first therapy targeting MCT8 deficiency, a rare disorder with high unmet need, and approval could provide a treatment option for patients with severe neurological and metabolic symptoms.

• The collaborative approach with the FDA and the drug's Breakthrough Therapy and Rare Pediatric Disease Designations may expedite review and access.